SYNLAB (DB:SYAB) - Share price, News & Analysis

SYAB fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	6/6
Financial Health	5/6
Dividends	3/6

SYAB Stock Overview

Rewards

Trading at 50.1% below our estimate of its fair value

Earnings grew by 190.1% over the past year

Risk Analysis

Earnings are forecast to decline by an average of 11.8% per year for the next 3 years

Unstable dividend track record

SYNLAB Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SYNLAB
Historical stock prices
Current Share Price	€16.69
52 Week High	€24.60
52 Week Low	€13.80
Beta	0
1 Month Change	-4.63%
3 Month Change	2.02%
1 Year Change	-7.79%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-15.39%

Recent News & Updates

May 29

SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market

SYNLAB AG ( FRA:SYAB ) shares have had a really impressive month, gaining 27% after a shaky period beforehand. But the...

May 20

SYNLAB (FRA:SYAB) Is Investing Its Capital With Increasing Efficiency

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...

Shareholder Returns

	SYAB	DE Healthcare	DE Market
7D	-5.2%	-5.2%	-1.2%
1Y	-7.8%	-30.3%	-23.0%

Return vs Industry: SYAB exceeded the German Healthcare industry which returned -30.3% over the past year.

Return vs Market: SYAB exceeded the German Market which returned -23% over the past year.

Price Volatility

Is SYAB's price volatile compared to industry and market?
SYAB volatility
SYAB Average Weekly Movement	6.1%
Healthcare Industry Average Movement	3.9%
Market Average Movement	5.6%
10% most volatile stocks in DE Market	9.8%
10% least volatile stocks in DE Market	2.9%

Stable Share Price: SYAB is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SYAB's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1998	25,750	Mathieu Floreani	https://www.synlab.com

SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers Coronavirus tests, and medical and veterinary diagnostics services. It operates through approximately 500 laboratories and 1,800 blood collection points in 36 countries in four continents.

SYNLAB Fundamentals Summary

How do SYNLAB's earnings and revenue compare to its market cap?
SYAB fundamental statistics
Market Cap	€3.71b
Earnings (TTM)	€653.14m
Revenue (TTM)	€3.89b

5.7x

P/E Ratio

1.0x

P/S Ratio

Is SYAB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
SYAB income statement (TTM)
Revenue	€3.89b
Cost of Revenue	€954.95m
Gross Profit	€2.93b
Other Expenses	€2.28b
Earnings	€653.14m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 11, 2022

Earnings per share (EPS)	2.94
Gross Margin	75.44%
Net Profit Margin	16.80%
Debt/Equity Ratio	57.1%

How did SYAB perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

11%

Payout Ratio

We’ve recently updated our valuation analysis.

Valuation

Is SYAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYAB?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SYAB. This is calculated by dividing SYAB's market cap by their current preferred multiple.
What is SYAB's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	€3.71b

SYAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.3x
Enterprise Value/EBITDA	4.8x
PEG Ratio	-0.5x

Price to Earnings Ratio vs Peers

How does SYAB's PE Ratio compare to its peers?

SYAB PE Ratio vs Peers

The above table shows the PE ratio for SYAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PE	Estimated Growth	Market Cap
Peer Average	22.6x

Forward PE

Price-To-Earnings vs Peers: SYAB is good value based on its Price-To-Earnings Ratio (5.7x) compared to the peer average (22.6x).

Price to Earnings Ratio vs Industry

How does SYAB's PE Ratio compare vs other companies in the Healthcare Industry?

Price-To-Earnings vs Industry: SYAB is good value based on its Price-To-Earnings Ratio (5.7x) compared to the German Healthcare industry average (15.4x)

Price to Earnings Ratio vs Fair Ratio

What is SYAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYAB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	5.7x
Fair PE Ratio	13.4x

Price-To-Earnings vs Fair Ratio: SYAB is good value based on its Price-To-Earnings Ratio (5.7x) compared to the estimated Fair Price-To-Earnings Ratio (13.4x).

Share Price vs Fair Value

What is the Fair Price of SYAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SYAB (€16.69) is trading below our estimate of fair value (€33.42)

Significantly Below Fair Value: SYAB is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: SYAB's earnings are forecast to decline next year, so we can't calculate its PEG ratio.

Discover undervalued companies

Future Growth

How is SYNLAB forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-11.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYAB's earnings are forecast to decline over the next 3 years (-11.8% per year).

Earnings vs Market: SYAB's earnings are forecast to decline over the next 3 years (-11.8% per year).

High Growth Earnings: SYAB's earnings are forecast to decline over the next 3 years.

Revenue vs Market: SYAB's revenue is expected to decline over the next 3 years (-0.2% per year).

High Growth Revenue: SYAB's revenue is forecast to decline over the next 3 years (-0.2% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SYAB's Return on Equity is forecast to be low in 3 years time (9.2%).

Discover growth companies

Past Performance

How has SYNLAB performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

63.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SYAB has high quality earnings.

Growing Profit Margin: SYAB's current net profit margins (16.8%) are higher than last year (7.3%).

Past Earnings Growth Analysis

Earnings Trend: SYAB has become profitable over the past 5 years, growing earnings by 63.5% per year.

Accelerating Growth: SYAB's earnings growth over the past year (190.1%) exceeds its 5-year average (63.5% per year).

Earnings vs Industry: SYAB earnings growth over the past year (190.1%) exceeded the Healthcare industry 44.5%.

Return on Equity

High ROE: SYAB's Return on Equity (26.3%) is considered high.

Discover strong past performing companies

Financial Health

How is SYNLAB's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: SYAB's short term assets (€1.6B) exceed its short term liabilities (€1.1B).

Long Term Liabilities: SYAB's short term assets (€1.6B) do not cover its long term liabilities (€2.2B).

Debt to Equity History and Analysis

Debt Level: SYAB's net debt to equity ratio (35.4%) is considered satisfactory.

Reducing Debt: SYAB's debt to equity ratio has reduced from 19359.5% to 57.1% over the past 5 years.

Debt Coverage: SYAB's debt is well covered by operating cash flow (70.3%).

Interest Coverage: SYAB's interest payments on its debt are well covered by EBIT (9.9x coverage).

Balance Sheet

Discover healthy companies

Dividend

What is SYNLAB current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

1.98%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: SYAB's dividend (1.98%) is higher than the bottom 25% of dividend payers in the German market (1.47%).

High Dividend: SYAB's dividend (1.98%) is low compared to the top 25% of dividend payers in the German market (4.57%).

Stability and Growth of Payments

Stable Dividend: Too early to tell whether SYAB's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if SYAB's dividend payments are increasing as they only just started paying a dividend.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (10.9%), SYAB's dividend payments are thoroughly covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (8.6%), SYAB's dividend payments are thoroughly covered by cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average board tenure

CEO

Mathieu Floreani (53 yo)

no data

Tenure

Mr. Mathieu Floreani serves as Chief Executive Officer at Synlab Limited since April 2018 and also serves as its Chairperson of the Management Board since 2021. Mr. Floreani has served as a Director of SYN...

Board Members

Experienced Board: SYAB's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/24 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31